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ABSTRACT 
Escitalopram Oxalate is a class of drug with selective serotonin (5-HT) reuptake 
inhibitor (SSRIs). SSRIs are broad spectrum antidepressants that are effective for 
major depressive disorder and several anxiety disorders. The main objective of the 
present study was to develop a pharmaceutically equivalent, stable, cost effective 
and quality improved formulation of immediate release tablets of Escitalopram 
Oxalate using different concentration of superdisintegrants like croscarmellose 
sodium and sodium starch glycolate. Preformulation studies were performed prior 
to formulation. The tablets were compressed using microcrystalline cellulose, 
colloidal silicon dioxide, talc, magnesium stearate and opadry white was used for 
coating the tablets. The tablets were formulated by wet granulation with non 
aqueous binder  and the fabricated tablets were evaluated for various micromeritic 
properties like bulk density, tapped density, compressibility index, Hausner’sratio, 
angle of repose and post compression characteristics like thickness, hardness, 
friability, disintegration time and drug release. Croscarmellose sodium was used 
as the disintegrant in the formulation of immediate release tablets of Escitalopram 
Oxalate. The stability studies were carried out for the optimized batch for six 
months. The results of the present study showed that among all the formulations, 
F12 was better in all terms of preformulation and post compression parameters 
and showed comparably a good dissolution profile like that of the marketed 
product(cipralex). 
 
Keywords: EscitalopramOxalate; antidepressants; wet granulation; stability 
studies. 
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AIM AND OBJECTIVE OF STUDY 
 
The aim of this work is to develop a stable and robust formulation of the drug 
Escitalopram Oxalate, which is an orally administered tablet with Antidepressant and Anxiolytic 
activity. 
The tablet produced should be a stable, bioequivalent to the Innovator sample (Cipralex). 
 To achieve this goal, various trials were performed and evaluated with respect to various 
quality parameters such as bulk density, sieve analysis, drug uniformity and dissolution. 
 
Objectives of the present study are 
 To design and develop an oral tablet dosage form comprising Escitalopram Oxalate API 
characterization. 
 Conducting Excipient Compatibility Studies. 
 Formulation development of tablets via selecting suitable tablet manufacturing method 
and different excipients. 
 Quality control of formulated tablets 
1. Testing for weight variation, hardness, thickness, friability, disintegration time 
etc. 
2. In vitro-dissolution study. 
 Comparison of optimized formulation tablets with commercial marketed tablets 
(Cipralex). 
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 Stability study of optimized formulation as per ICH guidelines of storage conditions for 
three months at 40 ºC/75 % RH, 30 ºC / 65 % RH and 25 ºC /60 % RH. 
 Evaluating Pharmaceutical Equivalence of formulated Tablets with that of the 
commercial formulation using dissimilarity (f1) and similarity (f2) factors. 
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1. INTRODUCTION 
Drugs are not generally given as pure chemical drug substances but are formulated as 
finished dosage forms (drug products) such as tablets, capsules, ointments, etc, before being 
administered to patients for therapy. Among these, tablets are the ruling dosage forms in the 
market. Formulated drug products usually include the active drug substance and selected 
ingredients (excipients) that make up the dosage form. Drug products are designed to deliver 
drug for local or systemic effects.1-2 
Over the last hundred years tablet manufacturers have developed materials and processes 
that can produce compressed tablet containing precise amount of an active pharmaceutical 
ingredient (API) at high speed and at relatively low cost. The development in the field of API, 
excipients, and tableting machinery during the past decade has made tablet manufacturing a 
science and tablets the most commonly used dosage form3 
1.1. Solid Dosage Forms4 
Solid dosage forms are widely prevalent due to their age-old application.  Especially, 
oral solid formulations hold a high potential as they serve to be most convenient for the 
administration of drugs.  These have been developed into a wide range of formulations from 
conventional dosage forms to targeted drug dosage forms. Oral route is the most convenient and 
commonly used method of drug delivery.  More than 50% of drug delivery systems available in 
the market are oral drug delivery systems. They offer convenience and ease of administration, 
greater flexibility in dosage form design and ease of production and low cost.  
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Pharmaceutical oral solid dosage forms have been used widely for decades mainly due 
to their convenience of administration and their suitability for delivery of drugs for systemic 
effects.  The most commonly used pharmaceutical solid dosage forms today include granules, 
pellets, tablets and capsules. 
These dosage forms are designed either for improving the physical and mechanical 
properties of materials during manufacture and/or for providing a desired drug delivery system.  
The tabletsand capsules can be made directly from powders or from granules and pellets, or 
from film coated multiple units. 
1.1.1 TABLETS5-10 
Tablet is defined as a compressed solid dosage form containing medicaments with or 
without excipients. According to the Indian Pharmacopoeia pharmaceutical tablets are solid, flat 
or biconvex dishes, unit dosage form, prepared by compressing a drug or a mixture of drugs, 
with or without diluents. They vary in shape and differ greatly in size and weight, depending on 
amount of medicinal substances and the intended mode of administration. It is the most popular 
dosage form and 70% of the total medicines are dispensed in the form of tablet. All 
medicaments are available in the tablet form except where it is difficult to formulate or 
administer.  
 
 
 
                                                                                                            
Introduction 
 
 Page 6 
 
1.1.2 ADVANTAGES OF TABLETS 
1. They are unit dosage form and offer the greatest capabilities of all oral dosage form for the 
greatest dose precision and the least content variability.  
2. Cost is lowest of all oral dosage form. 
3. Lighter and compact. 
4. Easiest and cheapest to package and strip.  
5. Easy to swallowing with least tendency for hang-up. 
6. Sustained release product is possible by enteric coating. 
7. Objectionable odour and bitter taste can be masked by coating technique.  
8. Suitable for large scale production. 
9. Greatest chemical and microbial stability over all oral dosage form. 
10. Product identification is easy and rapid requiring no additional steps when employing an 
embossed and/or monogrammed punch face. 
1.1.3 DISADVANTAGES OF TABLETS 
1. Difficult to swallow in case of children and unconscious patients.  
2. Some drugs resist compression into dense compacts, owing to amorphous nature, low density 
character.  
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3. Drugs with poor wetting, slow dissolution properties, optimum absorption high in GIT may 
be difficult to formulate or manufacture as a tablet that will still provide adequate or full drug 
bioavailability.  
4. Bitter tasting drugs, drugs with an objectionable odor or drugs that are sensitive to oxygen 
may require encapsulation or coating. In such cases, capsule may offer the best and lowest cost.   
1.1.4 CLASSIFICATION OF TABLETS  
Basing on the route of administered or the function, the tablets are classified as follows 
(A) Tablets ingested orally  
1. Compressed tablet, e.g. Paracetamol tablet  
2. Multiple compressed tablet 
i) Layered Tablets 
ii) Compression coated Tablets 
3. Repeat action tablet  
4. Delayed release tablet, e.g. Enteric coated Bisacodyl tablet  
5. Sugar coated tablet, e.g. Multivitamin tablet  
6. Film coated tablet, e.g. Metronidazole tablet  
7. Chewable tablet, e.g. Antacid tablet  
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(B) Tablets used in oral cavity 
1. Buccal tablet, e.g. Vitamin-C tablet  
2. Sublingual tablet, e.g. Vicks Menthol tablet  
3. Troches and lozenges  
4. Dental cones  
(C) Tablets administered by other route 
1. Implantation tablet  
2. Vaginal tablet, e.g. Clotrimazole tablet  
(D) Tablets used to prepare solution  
1. Effervescent tablet, e.g. Dispirin tablet (Aspirin)  
2. Dispensing tablet, e.g. Enzyme tablet (Digiplex)  
3. Hypodermic tablet  
4. Tablet triturates e.g. Enzyme tablet (Digiplex)  
1.1.5 EXCIPIENTS USED IN TABLETS 
In addition to active ingredients, tablet contains a number of inert materials known as additives 
or excipients. 
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1.2. Definition of excipients 
Excipients play a key role in transforming pharmacologically active substances into 
dosage forms, medicinal products and devices which are acceptable to the patient.   
The International Pharmaceutical Excipients Council (IPEC) defines excipients as 
Pharmaceutical excipients are any substance other than the active drug or prodrug that has been 
appropriately evaluated for safety and is included in a drug delivery system to either: 
1. Aid processing of the system during manufacture. 
2. Protect, support or enhance stability, bioavailability or patient acceptability. 
3. Assist in product identification. 
4. Enhance any other attribute of the overall safety and effectiveness of the drug product 
during storage or use.  
Salient features of excipients 
1. It should not accelerate the chemical and/or physical degradation of API(S). 
2. It should not interfere with the biological availability of active ingredient. 
3. It should be compatible with all the adjuvant present in the formulation. 
4. It should be physiologically inert. 
5. It should not interfere with the disintegration or dissolution of the active ingredient. 
6. It should be colorless and tasteless. 
7. It should be relatively cost effective and available in desired time. 
8. It should show batch-to-batch reproducibility of physical and physico-mechanical 
properties. 
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1.3.Formulation design and selection of excipients: 
The final composition of a product will be influenced by a range of factors, both objective 
and subjective. Many of the factors are interrelated. The final formulation will be a balance of 
all the factors. The choice of final product, e.g. hard gelatin capsule, tablet, coated tablet will 
often be dictated by factors outside the control of the formulator, via: 
 Company policy  
 Market research 
 Competitor products  
 Dose  
 Production preferences  
 Costs  
Different excipients are   
1. Diluents  
2. Binders and adhesives  
3. Disintegrents 
4. Lubricants  
5. Antiadherants 
6. Glidants 
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Table 1: Excipients with their functions in tablet formulation5, 8, 11 
EXCIPIENT FUNCTION 
Diluents or 
Fillers 
Diluents make the required bulk of the tablet when 
the drug dosage itself is inadequate to produce 
tablets of adequate weight and size. 
Binders or 
Granulating 
agents or 
Adhesives 
Binders are added to tablet formulations to add 
cohesiveness to powders, thus providing the 
necessary bonding to form granules, which under 
compaction form a cohesive mass or a compact 
which is referred to as a tablet. 
Disintegrants A disintegrant is added to most tablet formulations 
to facilitate a breakup or disintegration of the tablet 
when placed in an aqueous environment. 
Lubricants Lubricants are intended to reduce the friction during 
tablet formation in a die and also during ejection 
from die cavity. 
Antiadherents Antiadherents are added to reduce sticking or 
adhesion of any of the tablet granulation or powder 
to the faces of the punches or to the die wall. 
Glidants Glidants are intended to promote the flow of tablet 
granulation or powder mixture from hopper to the 
die cavity by reducing friction between the particles. 
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1. Diluents: Diluents are fillers used to make required bulk of the tablet when the drug dosage 
itself is inadequate to produce the bulk. Secondary reason is to provide better tablet properties 
such as improve cohesion, to permit use of direct compression manufacturing or to promote 
flow.  
Carbohydrate substances such as sugars, starches and celluloses may also function as 
binders during wet granulation process whereas when used in direct compression system, they 
serve as the diluent. The inorganic diluents, do not exhibit binding properties when used in wet 
granulation and direct compression. Tablet diluent or filler may also be classified on the basis of 
their solubility in water as soluble and insoluble.  
Table 2: Classification of diluents11, 12 
INSOLUBLE TABLET FILLERS OR 
DILUENTS 
SOLUBLE TABLET 
FILLERS OR DILUENTS 
Starch 
Powdered cellulose 
Microcrystalline cellulose 
Calcium phosphates 
Lactose 
Sucrose 
Mannitol 
Sorbitol 
 
Commonly used tablet diluents  
1. Lactose-anhydrous and spray dried lactose  
2. Directly compressed starch-Sta Rx 1500  
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3. Hydrolyzed starch-Emdex and Celutab 
4. Microcrystalline cellulose-Avicel (PH 101,PH 102 and PH 200)  
5. Dibasic calcium phosphate dehydrate  
6. Calcium sulphatedihydrate 
7. Mannitol 
8. Sorbitol  
9. Sucrose- Sugartab, DiPac, Nutab 
10. Dextrose  
 2. Binders and Adhesives13 
Binder is one of an important excipient to be added in tablet formulation. In simpler 
words, binders or adhesives are the substances that promote cohesiveness. It is utilized for 
converting powder into granules through a process known as Granulation. 
Purpose of Granulation14 
Powders/Granules intended for compression into tablets must possess two essential 
properties: flow property and compressibility. 
Flow property/Fluidity is required to produce tablets of a consistent weight and uniform 
strength. Compressibility is required to form a stable, intact compact mass when pressure is 
applied. These two objectives are obtained by adding binder to tablet formulation and then 
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proceeding for granulation process. Granules so formed should possess acceptable flow 
property and compressibility. Some drugs exhibit poor fluidity and compressibility. In such 
cases binders have to be added for improving flow property and compressibility. 
Other reasons for Granulation process are to improve appearance, mixing properties, to 
avoid dustiness, to densify material, to reduce segregation, in general to either eliminate 
undesirable properties or to improve the physical and chemical properties of fine powders. 
In wet granulation and dry granulation/slugging methods binders are added in 
solution/suspension form and in dry form respectively.  
In direct compression, binders possessing direct compressibility characteristics are used. Binder 
when used in liquid form gives better binding action as compared to when used in dry form. 
Table 3: Classification of binders15 
SUGARS NATURAL BINDERS SYNTHETIC/SEMISYNTHETIC POLYMERS 
Sucrose Acacia Methyl Cellulose 
Liquid 
Glucose 
Tragacanth Ethyl Cellulose 
-- Gelatin Hydroxy Propyl Methyl Cellulose ( HPMC) 
-- Starch Paste Hydroxy Propyl Cellulose 
-- Pregelatinized Starch Sodium Carboxy Methyl Cellulose 
-- Alginic Acid Polyvinyl Pyrrolidone (PVP) 
-- Cellulose Polyethylene Glycol (PEG) 
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-- -- Polyvinyl Alcohols 
-- -- Polymethacrylates 
3. DISINTEGRANTS13 
Disintegrants are added to a tablet formulation to facilitate its breaking or disintegration 
when it contacts water in the GIT. Disintegrants, an important excipient of the tablet 
formulation, are always added to tablet to induce breakup of tablet when it comes in contact 
with aqueous fluid and this process of desegregation of constituent particles before the drug 
dissolution occurs, is known as disintegration process and excipients which induce this process 
are known as disintegrants. The objectives behind addition of disintegrants are to increase 
surface area of the tablet fragments and to overcome cohesive forces that keep particles together 
in a tablet. 
Mechanism of TabletDisintegration11 
The tablet breaks to primary particles by one or more of the mechanisms listed below 
i. By capillary action 
ii. By swelling 
iii. Because of heat of wetting 
iv. Due to disintegrating particle/particle repulsive forces 
v. Due to deformation 
vi. Due to release of gases 
                                                                                                            
Introduction 
 
 Page 16 
 
vii. By enzymatic actionExample: Starch- 5-20% of tablet weight. Starch derivative – Primogel 
and Explotab (1-8%) Clays- Veegum HV, bentonite 10% level in colored tablet only Cellulose, 
Cellulose derivatives- Ac- Di-Sol (sodium carboxy methyl cellulose) 
Superdisintegrants16 
As days passes, demand for faster disintegrating formulation is increased. So, 
pharmacist needs to formulate disintegrants i.e. superdisintegrants which are effective at low 
concentration and have greater disintegrating efficiency and they are more effective 
intragranularly. Superdisintegrants swells up to ten fold within 30 seconds when contact water. 
But have one drawback that it is hygroscopic therefore not used with moisture sensitive drugs. 
Superdisintegrants act by swelling and due to swelling pressure exerted in the outer direction or 
radial direction, it causes tablet to burst or the accelerated absorption of water leading to an 
enormous increase in the volume of granules to promote disintegration.  
Table 4: List of superdisintegrants 
List of super 
disintegrants 
Example of 
Super disintegrants 
Mechanism 
of Action 
Special Comment 
Crosscarmellose® Ac-
Di-Sol® Nymce 
ZSX® Primellose® 
Solutab® Vivasol® 
Crosslinked cellulose -Swells 4-8 folds 
in < 10 seconds. -
Swelling and 
wicking both. 
-Swells in two dimensions. 
-Direct compression or 
granulation -Starch free 
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CrosspovidoneCrossp
ovidon M® 
Kollidon®  
Crosslinked PVP -Swells very little 
and returns to 
original size after 
compression but 
act by capillary  
-Water insoluble and 
spongy in nature so get 
porous tablet 
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2. DRUG PROFILE 
2.1.Escitalopram oxalate 
Escitalopram oxalate is an Antidepressant and also act as anxiolytic drug. Escitalopram oxalate 
is chemically designated as (1S)-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-3H-2-
benzofuran-5-carbonitrile oxalate, and it has the following chemical structure: 
 
 
Fig 1: Structural Formula of Escitalopram Oxalate 
The empirical formula is C20H21FN2O.C2H2O4, representing a molecular weight of 414.4. 
DESCRIPTION 
Escitalopram oxalate is a fine white to off-white powder. 
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SOLUBILITY 
Soluble in dimethyl formamide, dimethylsulfoxide, sparingly soluble in methanol and slightly 
soluble in dichloromethane. 
CLINICAL PHARMACOLOGY 
Mechanism of Action: Escitalopram is a selective inhibitor of serotonin (5-HT) re-uptake with 
high affinity for the primary binding site. It also binds to an allosteric site on the serotonin 
transporter, with a 1000 fold lower affinity. Escitalopram has no or low affinity for a number 
of receptors including 5-HT1A, 5-HT2, DA D1 and D2 receptors, α1-, α2-, β-adrenoceptors, 
histamine H1, muscarine cholinergic, benzodiazepine, and opioid receptors. The inhibition of 
5-HT re-uptake is the only likely mechanism of action explaining the pharmacological and 
clinical effects of Escitalopram. 
Pharmacokinetics: 
Absorption : 
Escitalopram is rapidly absorbed, with peak serum concentrations attained about 3–4 
hours after dosing. The pharmacokinetic profile of escitalopram is linear. The absolute 
bioavailability of Escitalopram is approximately 80%, implying limited first-pass metabolism, 
and co-administration of food does not affect the kinetics of escitalopram. Mean steady state 
concentrations following 10 mg/day are approximately 50 nmol/l. 
Distribution : 
Escitalopram is widely distributed, with an apparent volume of distribution of about 20 l/kg. 
Plasma protein binding is low (average 56%) over a wide range of concentrations, 
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Indicating a low potential for drug displacement interactions. 
Metabolism 
Escitalopram is metabolized by cytochrome P450 (CYP) enzymes to 
demethylEscitalopram, and further to barely detectable levels of didemethyl metabolite. By 
inference from results with racemic citalopram, the propionic acid derivative is a 
pharmacologically inactive metabolite, possibly formed by the action of monoamine oxidases. 
In addition, an N-oxide metabolite and glucuronides of citalopram have been identified. All of 
these derivatives are therapeutically inactive. The metabolism of escitalopram to 
desmethylescitalopram is mediated in parallel by three CYP isozymes: CYP3A4, 2C19  and 
2D6 whereas only CYP2D6 mediates further demethylation to the didemethyl metabolite.  
Elimination  
The escitalopram elimination half-life is about 30 hours, consistent with once-daily 
dosing, and the plasma clearance following oral administration is about 0.6 l/min .The 
pharmacokinetics is linear in the investigated dose range. The renal clearance values of 
escitalopram and it’sdemethyl metabolite are 2.7 and 6.9 l/h, respectively, corresponding to 
excretion of about 8% and 10% of the dose in urine. 
Drug Interactions: 
Contraindications: Hypersensitivity to escitalopram or to any of the excipients. Concomitant 
treatment with non-selective, irreversible monoamine oxidase inhibitors (MAO-inhibitors) is 
contraindicated due to the risk of serotonin syndrome with agitation, tremor, hyperthermia etc. 
The combination of escitalopram with reversibleMAO-A inhibitors (e.g. moclobemide) or the 
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reversible non-selectiveMAO-inhibitor linezolid is contraindicated due to the risk of onset of a 
serotonin syndrome. 
Mechanism of action  
The inhibition of serotonin (5-hydroxytryptamine; 5-HT) reuptake is the only mechanism of 
action explaining the pharmacological and clinical effects of escitalopram. Escitalopram is a 
selective inhibitor of serotonin reuptake, with high affinity for the primary binding site on the 
SERT protein, where conventional selective serotonin reuptake inhibitors (SSRIs) and the 
serotonin–noradrenaline reuptake inhibitors (SNRIs) venlafaxine and duloxetine bind. 
Escitalopram also binds to the allosteric site on SERT, which decreases the dissociation rate of 
escitalopram from the primary site, i.e. it appears to have a stabilising, or self-potentiating, 
effect on the escitalopram– transporter complex. This allosteric binding has led to escitalopram 
being described as an ASRI, an allosteric serotoninreuptake inhibitor The impact of R-
citalopram on escitalopram SERT binding. Pharmacological, functional and behavioural 
experiments have established that escitalopram (the S-enantiomer of citalopram) has a greater 
activity and an earlier onset of effect than its racemic parent, citalopram. The R-enantiomer, 
having negligible uptake-inhibiting effect in itself has recently been shown unexpectedly to 
inhibit the effect of the S-enantiomer on the SERT protein via an allosteric mechanism that 
decreases the time that S-citalopram occupies the primary site.In other words, one enantiomer 
appears to counteract the activity of the other at the same target a unique property among 
antidepressants.A recent in vitro study provided further evidence of R-citalopram’s allosteric 
effects at the human SERT (hSERT), by indicating that it produced a conformational change in 
the transporter protein. Moreover, in vitro binding studies showed that R-citalopram attenuated 
the association rates of Escitalopram and paroxetine (which is also known to act upon allosteric 
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sites, although to a lesser degree) with hSERT, but had no effect on the association rate of 
fluoxetine, which has no affinity for the SERT allosteric sites. 
Excipients Profile 
2.2. Microcrystalline Cellulose24 
Synonyms:  AvicelpH ,cellulose gel, crystalline cellulose, E460. 
Chemical Name: Cellulose  
Empirical Formula and Molecular Weight: (C6H10O5)n ≈36 000  where n ≈ 220. 
Structural Formula: 
 
Fig 2:Structural Formula of MCC 
Functional Category: Adsorbent, suspending agent, tablet and capsule diluent, tablet 
disintegrant. 
Description: 
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Microcrystalline cellulose is purified, partially depolymerized cellulose that occurs as a 
white, odorless, tasteless, crystalline powder composed of porous particles. It is commercially 
available in different particle sizes and moisture grades that have different properties and 
applications. 
Typical Properties 
Angle of repose: 49° 
Density (bulk): 0.32 g/cm3 
Density (tapped): 0.45 g/cm3 
Density (true): 1.512–1.668 g/cm3 
Flowability: 1.41 g/s 
Melting point: Chars at 260–270°C 
Moisture content: Typically less than 5% w/w. However, different grades may contain 
varying amounts of water. Microcrystalline cellulose is hygroscopic. 
Particle size distribution: Typical mean particle size is 20–200 μm. Different grades may 
have a different nominal mean particle size. 
Solubility: Slightly soluble in 5% w/v sodium hydroxide solution, practically insoluble in 
water, dilute acids, and most organic solvents. 
Specific surface area: 1.06–1.12 m2/g 
Applications in Pharmaceutical Formulation or Technology: 
Drug and Polymer Profile 
 
 Page 24 
 
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a binder/diluent in 
oral tablet and capsule formulations where it is used in both wet-granulation and direct-
compression processes. In addition to its use as a binder/diluent, microcrystalline cellulose also 
has some lubricant and disintegrant properties that make it useful in tableting. Microcrystalline 
cellulose is also used in cosmetics and food products. 
Table 5: Uses of microcrystalline cellulose 
Use Concentration (%) 
Adsorbent 20–90 
Antiadherent 5–20 
Capsule binder/diluents 20–90 
Tablet disintegrant 5–15 
Tablet binder/diluents 20–90 
Stability and Storage Conditions: Microcrystalline cellulose is a stable though hygroscopic 
material. The bulk material should be stored in a well-closed container in a cool, dry place. 
Incompatibilities: Microcrystalline cellulose is incompatible with strong oxidizing agents. 
2. 3.Hydroxy Propyl Methyl Cellulose (Methocel E-5) 25 
Synonyms: Hydroxypropyl methylcellulose, HPMC, methylcellulose propylene glycol ether, 
methyl hydroxypropylcellulose. 
Chemical Name: Cellulose hydroxypropyl methyl ether  
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Empirical Formula and Molecular Weight: CH2CH(OH)CH3, calculated on a dried basis.  
Molecular weight is approximately 10,000–1,500,000.  
Structural Formula 
 
 
 
Fig 3: Structural Formula of HPMC(E5) 
Where R is H, CH3, or CH3CH(OH)CH2 
Functional Category: Coating agent, film-former, rate-controlling polymer for sustained 
release, stabilizing agent, suspending agent, tablet binder, viscosity-increasing agent. 
Description: Hypromellose is an odorless and tasteless, white or creamy-white fibrous or 
granular powder.  
Typical Properties 
Acidity/alkalinity: pH = 5.5–8.0 for a 1% w/w aqueous solution. 
Ash: 1.5–3.0%, depending upon the grade and viscosity. 
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Auto ignition temperature: 360°C 
Density (bulk): 0.341 g/cm3 
Density (tapped): 0.557 g/cm3 
Density (true): 1.326 g/cm3 
Melting point: Browns at 190–200°C, chars at 225–230°C. Glass transition temperature is 
170–180°C. 
Moisture content: Hypromellose absorbs moisture from the atmosphere; the amount of water 
absorbed depends upon the initial moisture content and the temperature and relative humidity 
of the surrounding air.  
Solubility   
Soluble in cold water, forming a viscous colloidal solution, practically insoluble in chloroform, 
ethanol (95%), and ether, but soluble in mixtures of ethanol and dichloromethane, mixtures of 
methanol and dichloromethane, and mixtures of water and alcohol. Certain grades of 
hypromellose are soluble in aqueous acetone solutions, mixtures of dichloromethane and 
propan-2-ol, and other organic solvents.  
Specific gravity: 1.26 
Applications in Pharmaceutical Formulation or Technology 
Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical formulations. In 
oral products, hypromellose is primarily used as a tablet binder, in film-coating, and as a 
matrix for use in extended-release tablet formulations. Hypromellose is also used as a 
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suspending and thickening agent in topical formulations. Hypromellose is also used as an 
emulsifier, suspending agent, and stabilizing agent in topical gels and ointments. 
Stability and Storage Conditions 
Hypromellose powder is a stable material, although it is hygroscopic after drying solutions are 
stable at pH 3–11. Increasing temperature reduces the viscosity of solutions. Hypromellose 
undergoes a reversible sol–gel transformation upon heating and cooling, respectively. The gel 
point is 50–90°C, depending upon the grade and concentration of material. Hypromellose 
powder should be stored in a well-closed container, in a cool, dry place. 
Incompatibilities 
Hypromellose is incompatible with some oxidizing agents. Since it is nonionic, hypromellose 
will not complex with metallic salts or ionic organics to form insoluble precipitates. 
2.4.Sodium starch glycolate 
Synonyms: Carboxymethyl starch, sodium salt; carboxymethylamylumnatricum; Explosol; 
Explotab; Glycolys; Primojel; starch carboxymethyl ether, sodium salt; Tablo; Vivastar P. 
Chemical Name: Sodium carboxymethyl starch 
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Structural Formula 
 
Fig 4: Structural Formula of Sodium Starch Glycolate 
Functional Category: Tablet and capsule disintegrant. 
Description: Sodium starch glycolate is a white to off-white, odorless, tasteless, free-flowing 
powder. The PhEur 2005 states that it consists of oval or spherical granules, 30–100 mm in 
diameter, with some less-spherical granules ranging from 10–35 mm in diameter. 
Typical Properties 
Acidity/alkalinity: pH = 5.0–7.0 in aqueous dispersions. 
Density (bulk): 0.529 g/cm3 
Density (tapped): 0.819 g/cm3 
Density (true): 1.543 g/cm3 
Particle size distribution: NMT 2% retained on a #200 (73.7 μm) mesh and not more than 
10% retained on a #325 (44.5 μm) mesh. 
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Solubility: Insoluble in water, although sodium starch glycolate rapidly swells to 4–8 times its 
original volume on contact with water. Practically insoluble in acetone, ethanol and toluene. 
Specific surface area: 0.81–0.83 m2/g 
Applications in Pharmaceutical Formulation or Technology 
Sodium starch glycolate is used in oral pharmaceutical formulations as a disintegrant for 
capsules, tablets and granules. 
In tablet formulations, sodium starch glycolate may be used in both direct-compression and 
wet-granulation processes. When used in wet granulations, the sodium starch glycolate should 
be added in both the wet and dry stages of the process (intra- and extra granularly) so that the 
wicking and swelling ability of the disintegrant is best utilized. sodium starch glycolate at 
concentrations up to 5% w/w may be used as a tablet disintegrant, although normally 2% w/w 
is used in tablets prepared by direct compression and 3% w/w in tablets prepared by a wet-
granulation process.  
  Table 6: Uses of sodium starch glycolate 
Use Concentration (%) 
Disintegrant in capsules 10–25 
Disintegrant in tablets 0.5–5.0 
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Stability and Storage Conditions 
Sodium starch glycolate is a stable though hygroscopic material. 
A model tablet formulation prepared by direct compression, with sodium starch glycolate  as a 
disintegrant, showed no significant difference in drug dissolution after storage at 30°C for 14 
months. 
sodium starch glycolate should be stored in a well-closed container in a cool, dry place. 
Incompatibilities 
The efficacy of disintegrants, such as sodium starch glycolate, may be slightly reduced in tablet 
formulations prepared by either the wet-granulation or direct-compression process that contain 
hygroscopic excipients such as sorbitol. 
Sodium starch glycolate is not compatible with strong acids or with soluble salts of iron and 
some other metals such as aluminum, mercury, and zinc. 
2.5. Colloidal Silicondioxide26 
Synonyms: Aerosil, Cab-O-Sil, Cab-O-Sil M-5P, colloidal silica, fumed silica, fumed silicon 
dioxide, SAS, silica colloidalisanhydrica, silica sol, silicic anhydride, silicon dioxide colloidal, 
silicon dioxide fumed, synthetic amorphous silica, Wacker HDK. 
Chemical Name: Silica 
Empirical Formula and Molecular Weight: SiO2 and 60.08 
Structural Formula: [CH3(CH2)16COO]2Mg 
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Functional Category: Adsorbent, anticaking agent, emulsion stabilizer, glidant, suspending 
agent, tablet disintegrant, thermal stabilizer, viscosity-increasing agent. 
Description: 
Colloidal silicon dioxide is submicroscopic fumed silica with a particle size of about 15 nm. It 
is a light, loose, bluish-white-colored, odorless, tasteless, amorphous powder. 
Typical Properties 
Acidity/alkalinity pH: 3.8–4.2 (4% w/v aqueous dispersion) and 3.5–4.0 (10% w/v aqueous 
dispersion) for Cab-O-Sil M-5P 
Density (bulk): 0.029–0.042 g/cm3 
Melting point: 16000C 
Particle size distribution: Primary particle size is 7–16 nm. Aerosil forms loose agglomerates 
of 10–200 mm.  
Refractive index: 1.46 
Solubility: Practically insoluble in organic solvents, water, and acids, except hydrofluoric acid, 
soluble in hot solutions of alkali hydroxide. Forms a colloidal dispersion with water. For 
Aerosil, solubility in water is 150 mg/L at 258C (pH 7). 
Specific gravity: 2.2 
Specific surface area: 100–400 m2/g depending on grade.  
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Applications in Pharmaceutical Formulation or Technology: 
Colloidal silicon dioxide is widely used in pharmaceuticals, cosmetics, and food products. Its 
small particle size and large specific surface area give it desirable flow characteristics that are 
exploited to improve the flow properties of dry powders in a number of processes such as 
tableting and capsule filling. Colloidal silicon dioxide is also used to stabilize emulsions and as 
a thixotropic thickening and suspending agent in gels and semisolid preparations. With other 
ingredients of similar refractive index, transparent gels may be formed. The degree of viscosity 
increase depends on the polarity of the liquid (polar liquids generally require a greater 
concentration of colloidal silicon dioxide than nonpolar liquids). Viscosity is largely 
independent of temperature. However, changes to the pH of a system may affect the viscosity 
in aerosols, other than those for inhalation, colloidal silicon dioxide is used to promote 
particulate suspension, eliminate hard settling, and minimize the clogging of spray nozzles. 
Colloidal silicon dioxide is also used as a tablet disintegrant and as an adsorbent dispersing 
agent for liquids in powders. Colloidal silicon dioxide is frequently added to suppository 
formulations containing lipophilic excipients to increase viscosity, prevent sedimentation 
during molding, and decrease the release rate. Colloidal silicon dioxide is also used as an 
adsorbent during the preparation of wax microspheres, as a thickening agent for topical 
preparations, and has been used to aid the freeze-drying of nanocapsules and nanosphere 
suspensions. 
Table 7: Uses of colloidal silicon dioxide. 
Use Concentration (%) 
Aerosols 0.5–2.0 
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Emulsion stabilizer 1.0–5.0 
Glidant 0.1–1.0 
Suspending and thickening agent 2.0–10.0 
 
Stability and Storage Conditions: 
Colloidal silicon dioxide is hygroscopic but adsorbs large quantities of water without 
liquefying. When used in aqueous systems at a pH 0–7.5, colloidal silicon dioxide is effective 
in increasing the viscosity of a system. However, at a pH greater than 7.5 the viscosity 
increasing properties of colloidal silicon dioxide are reduced, and at a pH greater than 10.7 this 
ability is lost entirely since the silicon dioxide dissolves to form silicates. Colloidal silicon 
dioxide powder should be stored in a well-closed container. 
Incompatibilities: 
Incompatible with diethylstilbestrol preparations. 
2.6. Magnesium Stearate27 
Synonyms: Magnesium octadecanoate, octadecanoic acid, magnesium salt, stearic acid, 
magnesium salt. 
Chemical Name: Octadecanoic acid magnesium salt  
Empirical Formula and Molecular Weight: C36H70MgO4, 591.34 
Structural Formula: [CH3(CH2)16COO]2Mg 
Functional Category: Tablet and capsule lubricant. 
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Description: 
Magnesium stearate is a very fine, light white, precipitated or milled, impalpable 
powder of low bulk density, having a faint odor of stearic acid and a characteristic taste. The 
powder is greasy to the touch and readily adheres to the skin. 
Typical Properties 
Crystalline forms: High-purity magnesium stearate has been isolated as a trihydrate, a 
dihydrate, and an anhydrate. 
Density (bulk): 0.159 g/cm3 
Density (tapped): 0.286 g/cm3 
Density (true): 1.092 g/cm3 
Flash point: 250°C 
Flowability: Poorly flowing, cohesive powder. 
Melting range: 126–130°C 
Solubility: Practically insoluble in ethanol, ethanol (95%), ether and water, slightly soluble in 
warm benzene and warm ethanol (95%). 
Specific surface area: 1.6–14.8 m2/g 
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Applications in Pharmaceutical Formulation or Technology 
Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical formulations. It is 
primarily used as a lubricant in capsule and tablet manufacture at concentrations between 
0.25% and 5.0% w/w. It is also used in barrier creams. 
Stability and Storage Conditions 
Magnesium stearate is stable and should be stored in a well-closed container in a cool, dry 
place. 
Incompatibilities 
Incompatible with strong acids, alkalis, and iron salts. Avoid mixing with strong oxidizing 
materials. Magnesium stearate cannot be used in products containing aspirin, some vitamins, 
and most alkaloidal salts. 
 
2.7.Isopropyl  alcohol 
Synonyms: Alcohol isopropylicus, dimethyl carbinol, IPA, isopropanol, petrohol,2-
propanol,sec-propyl alcohol; rubbing alcohol. 
Chemical Name: Propan-2-ol 
Empirical Formula and Molecular Weight: C3H8O 60.1 
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Structural Formula 
Fig 5: Structural Formula of IPA  
Functional Category: Disinfectant, solvent. 
Description: Isopropyl alcohol is a clear, colorless, mobile, volatile, and flammable liquid 
with a characteristic, spirituous odor resembling that of a mixture of ethanol and acetone; it has 
a slightly bitter taste. 
Typical Properties 
Antimicrobial activity Isopropyl alcohol is bactericidal, at concentrations greater than 70% v/v 
it is a more effective antibacterial preservative than ethanol (95%). The bactericidal effect of 
aqueous solutions increases steadily as the concentration approaches 100% v/v. Isopropyl 
alcohol is ineffective against bacterial spores.  
Boiling point 82.48°C 
Dielectric constant D20 = 18.62 
Flash point 11.78C (closed cup); 138C (open cup). 
Melting point _88.58 
Solubility  Miscible with benzene, chloroform, ethanol (95%), ether, glycerin, and water. 
Soluble in acetone; insoluble in salt solutions.Forms an azeotrope with water, containing 
87.4% w/w isopropyl alcohol (boiling point 80.378C). 
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Specific gravity 0.786 
Viscosity (dynamic) 2.43 mPa s (2.43 cP) at 208C 
Applications in Pharmaceutical Formulation or Technology 
Isopropyl alcohol is used in cosmetics and pharmaceutical formulations, primarily as a 
solvent in topical formulations. It is not recommended for oral use owing to its toxicity, 
Although it is used in lotions, the marked degreasing properties of isopropyl alcohol may limit 
its usefulness in preparations used repeatedly. Isopropyl alcohol is also used as a solvent both 
for tablet film-coating and for tablet granulation, where the isopropyl alcohol is subsequently 
removed by evaporation. It has also been shown to significantly increase the skin permeability 
of nimesulide from carbomer 934.Isopropyl alcohol has some antimicrobial activity and a 70% 
v/v aqueous solution is used as a topical disinfectant. Therapeutically, isopropyl alcohol has 
been investigated for the treatment of postoperative nausea or vomiting. 
Stability and Storage Conditions 
Stability and Storage Conditions Isopropyl alcohol should be stored in an airtight container in a 
cool, dry place. 
Incompatibilities 
Incompatible with oxidizing agents such as hydrogen peroxide and nitric acid, which cause 
decomposition. 
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 3. LITERATURE REVIEW 
1. SrinivasGangula et.Al17 worked on identification, synthesis and spectral 
characterization of impurities in process development of Escitalopram, identified, synthesized 
(starting from racemic substrates), developed robust analytical methods and characterized the four 
process related impurities present in escitalopram particularly those are close to 0.10%. The 
characterization of these compounds is based on LC–MS, IR and NMR spectral data followed by 
their independent syntheses in order to meet the regulatory requirements as per ICH guidelines. 
 
2. Patrick Crowley18 identified the Drug Excipient interactions, although considered 
pharmacologically inert, excipients can initiate, propagate or participate in chemical or physical 
interactions with drug compounds, which may compromise the effectiveness of a medication. 
Excipients may also contain impurities or form degradation products that in turn cause 
decomposition of drug substances.  Here interactions are necessary prerequisite to the 
development of dosage forms that are stable and of good quality. 
 
3. N. Dogan and T.H.Mchugh19worked on the Effects of Microcrystalline Cellulose on 
Functional Properties of Hydroxy Propyl Methyl Cellulose Microcomposite Films, investigate the 
use of nanosize MCC fillers for the purpose of preparing edible microcomposite films. It was 
shown that through the incorporation of fillers such as MCC, edible film mechanical properties 
can be significantly improved without reducing film barrier properties. These findings are 
expected to have a significant impact on the food industry by enabling them to manufacture edible 
films with improved tensile strengths, while maintaining their elongation and water vapor 
permeability values. The size, configuration, and water bonding properties of filler materials as 
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well as their compatibility with the matrix affect the microstructure and overall functional 
properties of films. These results will allow food scientists to envision a new generation of 
composite edible films and barriers and not be restricted to emulsified and bilayer films for 
current and new applications. 
 
4. Hareesha chamarthi20worked on Formulation and evaluation of oro dispersible tablet of 
Escitalopram oxalate by super disintegrates addition method, direct compression method is useful 
for the preparation for oro dispersible tablet of Esitalopram oxalate. crosscarmellose sodium and 
crosspovidone mixture is useful for this preparation. 
 
5. Ngoc Do, Jason Hansell, and Thomas P. Farrell21worked on Modulating Dissolution 
Profiles of Immediate Release Tablets Using Methocel E5 LV and a Direct Compression Process, 
The drug release rate of tablets depends on several formulation variables such as the concentration 
and viscosity of the polymers as well as the concentration and water solubility of the drugs. The 
purpose of this study was to investigate the ability of  singleMethocel premium cellulose ether, E5 
LV grade to modulate the dissolution profiles of immediate release tablets prepared by different 
types of compression methods. The dissolution rate of all tablets decreases with increasing 
concentration of Methocel E5 LV. The slow-down effect of Methocel E5 LV also depends on the 
water solubility characteristics of the drug – i.e. lower water solubility drugs had slower 
dissolution rates at the highest METHOCEL E5 LV concentrations. Film coating with Opadry II 
85 Series has no effect on the dissolution profiles of all tablets containing METHOCEL E5 LV... 
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6. Rohokale BS, Jadhav VM, Kadam VJ22worked related to the studies in optimization of 
non aqueous film coating parameters. At lower spray rate un-uniform coating was reported and at 
high rate white spot, sticking and picking problem was recorded. Variation in atomization air 
pressure affect over quality of coating process because at high atomization air pressure small 
droplet was formed and at low atomization air pressure big droplet was formed. As distance 
between tablet bed and spray gun increased disturbed spray spray pattern was observed even at 
minimum distance sticking & white spot over tablet noted. At low inlet air temperature rough 
surface, sticking, picking & white spot was observed and at high temperature white spot & rough 
surface observed. As pan DP reduced spray was disturbed. Higher RPM of pan increase the 
mixing and distributions of spray over the tablet. At high % solid content create problem like 
roughness over tablet.  
 
7. Suresh Pareek, ChetanRajsharad, Ashok Mohanty&Aditi Golatkar23worked on 
theEffect of solvents on tablet coating. The film coating of Pharmaceutical dosage forms is done 
by dispersing the polymers, plasticizers, opacifier Lubricant & pigments or Ready to use film 
coating material like Instacoat in the solvent system. The solvent system could be Organic, 
Aqueous or a combination of Organic and Aqueous. The most commonly used organic solvents 
are IPA and Methylene chloride. The Instacoat coating material used for conducting various 
coating trials proved to the effect in different type of solvent system. It proved to be very coat 
effective in case of aqueous coating. The final product finish was also much better in case of 
aqueous coating in White colour. In case of Indigo carmine, the colour shade of the finish product 
should be decided based on the solvent system. 
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8. Sanil Kumar Ramachandra Nair,2012Escitalopram Oxalate is a class of drug with 
selective serotonin (5-HT) reuptake inhibitor (SSRIs). The tablets were compressed using 
microcrystalline cellulose, colloidal anhydrous silica, croscarmellose sodium, talc, magnesium 
stearate and opadry white was used for coating the tablets. The tablets were formulated by direct 
compression. Croscarmellose sodium was used as the disintegrant in the formulation of 
immediate release tablets of Escitalopram Oxalate. The stability studies were carried out for the 
optimized batch for six months. The results of the present study showed that among all the 
formulations, F4 was better in all terms of preformulation and post compression parameters and 
showed comparably a good dissolution profile like that of the marketed product. 
9. Ramesh Kannuri1*, HareeshaChamarthi2 ,2012 developed Orally disintegrating 
tablets of escitalopram Oxalate. Orally disintegrating tablets offers a solution for paediatrics, 
geriatrics; psychiatric or mentally ill people and those have difficulty in swallowing 
tablets/capsules resulting in improved patient compliance. The aim is to formulate Orally 
disintegrating tablets of escitalopram oxalate using different ratios of Superdisintegrants LHPC-
21, Kyron and Crospovidone, while Microcrystalline cellulose, Mannitol, Prosolv ODT used as 
fillers. Tablets were prepared by direct compression method. The tablets were evaluated for 
hardness, thickness, friability, and weight variation and disintegration time, dispersion times and 
%drug release studies were performed. Tablets containing Crospovidone, Kyron as disintegrants 
and Mannitol as filler were disintegrate rapidly below 20 sec and 100% drug release below 5mins. 
10. Suneetha.A,2011A simple, specific, accurate and precise RP-HPLC method was 
developed and validated for the determination of escitalopram oxalate in tablet dosage forms. A 
hypersil BDS C8, 5- column having 250x4.6mm internal diameter in isocratic mode with mobile 
phase containing methanol: disodium hydrogen phosphate: acetonitrile (28:44:28v/v, pH 
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7.0±0.05) was used. The flow rate was 1.5ml/min and effluents were monitored at 226nm. The 
retention time of escitalopram oxalate was 8.45 min. The linearity range is 250-1500-g/ml with 
coefficient of correlation 0.9999. The method was validated in terms of accuracy, precision, 
repeatability. The percentage recovery for escitalopram oxalate was found to be 99.0%. The 
proposed method was successfully applied for quantitative determination of escitalopram oxalate 
in single dosage form for routine analysis. 
11. Patel, JigarA, et al. prepared immediate release tablets using a suitable diluents and 
super-disintegrants. Faster disintegration of the tablet administrated orally minimizes absorption 
time and improves its bioavailability in less time. Immediate Release tablet of Antibiotic drug is 
formulated using dry granulation using super disintegrantcroscarmellose sodium. One of the 
important studies included in the present investigation is of study on process parameter effect on 
performance of the Immediate Release tablets. The effect of selected process parameters on 
critical properties of immediate release (IR) tablets were studied, like effect of disintegration time, 
friability, dissolution profile. The optimized formulation F5 was evaluated for in vitro drug 
release in pH 5.0, 6.8 for 60min using BP type II dissolution apparatus at 50 rpm. Hence 
Antibiotic drug can be successfully formulated as an immediate release tablet by dry granulation 
method. 
12. B.G.Shiyaniet al., 2009 compares the disintegrants efficiency of the 3  
superdisintegrants(Ac-Di-Sol, Polyplasdone XL and Explotab) and also to compare disintegrant 
properties disintegrant efficiency of agar (AG) and gellan gum (GG) with treated agar (TAG) and 
treated gellan gum (TGG) by formulating metoclopramide HCl immediate release tablets by 
direct compression method. In the present investigation, the attempted first time reporting TGG as 
disintegrant. Disintegration efficiency of powder disintegrants were compared by swelling 
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&hydration capacity of disintegrants. While efficiency of disintegrants in tablets compared by 
various test like disintegration time, dissolution test, wetting time & maximal water uptake study 
of metoclopramide HCl immediate release tablets. 
13. Biljana Govedarica,2011,Paracetamol (PAR) crystals exhibit poor compressibility, poor 
flowability and its tablets show a tendency to cap. To improve the mechanical strength of tablets 
several kinds of “Paracetamol for direct compression” are present on the market. Current research 
demonstrated the best tablet properties with coated paracetamol, Furthermore, coated paracetamol 
in combination with both investigated superdisintegrants such as Vivasol® and Polyplasdone® 
XL-10 shows faster disintegration time and dissolution rate in comparison to paracetamol for 
direct compression. Eventually, the major advantages of the formulation with coated paracetamol 
for industrial production are decrease of friability and superiority in terms of flowability, 
compressibility, quick disintegration and dissolution.  
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4.Materials and Equipment 
4.1.List of Materials Used 
The materials and their supplier names which are used in the formulation development of 
Escitalopram oxalate  Immediate  Release tablets are listed below. 
Table 8: List of Materials used 
 
 
S. No. MATERIAL NAME OF SUPPLIER 
1. Escitalopram oxalate Finoso Pharma Pvt. Limited 
2. Microcrystalline cellulose FMC Biopolymer 
3. Hydroxypropyl methyl cellulose Dow Chemical Company 
4. Isopropyl alcohol Rankem limited 
5. Croscarmellose sodium FMC Biopolymer 
6 Colloidal silicon dioxide Evonik Degussa 
7. Magnesium stearate Ferro corporation, Cleveland 
8. Opadry white Colorcon 
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4.2. List of EquipmentsThe following are the list of equipments used for the formulation 
development.       
Table 9: List of Instruments used 
S.No. Name of Instrument Manufacturer 
1  Automatic tablet dissolution apparatus USP II Electro lab 
2  Digital Vernier calipers Fischer scientific 
3  Friability tester Electrolab 
4  Tablet hardness tester 
Dr Schleunizer tablet tester 
8m 
5  Halogen Moisture Analyzer Sartorious MA 100 
6  Electro magnetic sieve shaker Electrolab 
7  Tap Density Apparatus Electrolab 
8  Mini roll compactor Chamunda 
9  Electronic weighing balance 
SartoriousPrecision 
balance 
10  17 station rotatory tabletting machine Cadmach 
11  Coating machine Neocota 
12  Rapid dryer Retsch 
13  Moisture Content ( KF Titrino ) Metrohm 
14  UV – Spectrometer Shimadzu 
15  High pressure liquid chromatographic apparatus Azulent 
16  pH meter Thermo 
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4.3.PREFORMULATION STUDY 
Preformulation study was an investigation of physical and chemical properties of a drug 
substance alone and when combined with excipients. It was the first step in the rational 
development of dosage forms. 
4.3.1. Objective /Purpose of Preformulation study:-  
Pre-formulation studies on active pharmaceutical ingredients (API), inactive ingredients 
(Excipients), and their combinations were carried out to serve following purposes: 
i) To Finalize specifications of active pharmaceutical ingredients (API) 
ii) To Study the compatibility between active and inactive ingredient 
iii) Characterization of reference product. 
4.3.2. Scope:- 
The use of preformulation parameters maximizes the chances in formulating an 
acceptable, safe, efficacious and stable product. 
4.3.3. Class: - Preformulation study can divide in to two Subclasses. 
4.3.3.1 API characterization,  
      4.3.3.2. Compatibility study 
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4.3.3.1. Active pharmaceutical ingredient (API) characterization:- 
Organoleptic Evaluation:-These are preliminary characteristics of any substance which is 
useful in identification of specific material. Following physical properties of   API were 
studied.   
a) Color  
  b) Odor  
Table 10: Organoleptic and Solubility Analysis of Escitalopram Oxalate 
Parameter Escitalopram Oxalate 
Organoleptic Evaluation White to off white  powder 
Solubility Analysis 
Soluble in dimethyl 
formamide, 
dimethylsulphoxide, 
sparingly soluble in methanol 
and slightly soluble in 
dichloromethane. 
 
Loss on drying:-1.5g of sample of Escitalopram Oxalate was accurately weighed and the 
powder was kept in a moisture balance apparatus for 5 min at 105ºC and the moisture content 
was calculated. 
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Bulk density:- 
Bulk density was determined by pouring gently 25 gm of sample (Escitalopram Oxalate) into 
100 ml graduated cylinder. The volume occupied by the sample was recorded. Bulk density 
was calculated as: 
        
 Tapped density:-   
Tapped density was determined by using Electro lab density tester, which consists of   a 
graduated cylinder mounted on a mechanical tapping device. An accurately weighed sample 
of powder was carefully added to the cylinder. Typically, the initial volume was noted, and 
the sample is then tapped (500, 750 or 1250 tapping) until no further reduction in volume is 
noted or the percentage of difference is not more than 2%. 
A sufficient number of taps should be employed to assure reproducibility for the material in 
question.                     
Volume was noted and tapped density is calculated using following formula. 
 
 
Compressibility Index and Hausner ratio:- 
In recent years the compressibility index and the closely related Hausner ratio have 
become the simple, fast, and popular methods of predicting powder flow characteristics.  
Bulk density = weight of sample in gram /volume occupied by the sample 
sample 
Tapped density = Wt. of sample in gm / Tapped volume 
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Both the compressibility index and the Hausner ratio were determined by using bulk density 
and the tapped density of a powder.      
 
 
100
density  Tapped
density Bulk desnity Tapped
 index  sCarr' 


 
Table no.11: Relation of flow property with HR & CI 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compressibility 
      Index (%) 
Flow                             
Character 
Hausner’s Ratio 
10 Excellent 1.00–1.11 
11–15 Good 1.12–1.18 
16–20 Fair 1.19–1.25 
21–25 Passable 1.26–1.34 
26–31 Poor 1.35–1.45 
32–37 Very poor 1.46–1.59 
>38 Very very poor >1.60 
C.I=tapped density-untapped density*100/tapped density. 
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Angle of Repose:  
The angle of repose has been used to characterize the flow properties of solids. Angle of 
repose is a characteristic related to inter particulate friction or resistance to movement 
between particles. This is the maximum angle possible between surface of pile of powder or 
granules and the horizontal plane.  
                                      Tan  = h / r 
 = Tan –1 h / r 
                         Where  = angle of repose, h = height, r = radius.  
A funnel was fixed at a height approximately of 2-4 cm over the platform. The loose 
powder was slowly passed along the wall of funnel, till the cone of the powder formed 
.Determine the angle of repose by measuring the height of the cone of powder and radius of 
the heap of powder. 
Table 12: Flow Properties and Corresponding Angles of Repose 
 
 
 
 
 
 
 
Flow Property Angle of Repose (degrees) 
Excellent 25–30 
Good 31–35 
Fair - aid not needed 36–40 
Passable - may hang up 41–45 
Poor - must agitate, vibrate 46–55 
Very poor 56–65 
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Table 13: Flow properties of Escitalopram Oxalate (API) 
Parameters 
Bulk density 0.199 gm/ml 
Tap density 0.384 gm/cc 
Compressibility / Carr’s index (%) 48% 
Hausner’s ratio 0.1923 
Angle of repose 44.625 
 
From the above results it is evident that the drug has very poor flow properties, as the 
compressibility index, Hausner’s ratio and Angle of repose values are high.  
Particle size: 
Sieve analysis: 
The main aim of sieve analysis is to determine the different size of drug particles present. A 
series of standard sieves were stacked one above the other so that sieves with larger pore size 
(less sieve number) occupy top position followed by sieves of decreasing pore size (larger 
sieve number) towards the bottom. 
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Procedure: Clean and dry#60,  80,  100,  120, and collector were collected and individual 
weights of each sieve were noted. These sieves were arranged in ascending order. Weighed 
quantity of Escitalopram Oxalate (100gm) was placed in 60 mesh. Sieve shaker was set for 5 
min at amplitude of 40 (Intermittent shaking). 
 Remove the set up from the sieve shaker after 5 min and weigh the each mesh individually 
and calculate % drug retained in each size of mesh with the following formula.  
   
       Final weight – initial weight 
                   % Retained =    ---------------------------------------     x 100 
     Total weight taken 
Sieve analysis of Escitalopram Oxalate 
Table 14: Results of sieve analysis 
Sieve No. 
Sieve size 
(micron) 
Initial Wt. (gm) 
Final Wt. 
(gm) 
% Retained 
#60 250 269.5 271 1.5 
#80 180 247.5 254.0 6.5 
#100 150 268.5 279.0 42 
#120 125 238.0 250.5 50 
Collector 343.5 343.5 0 
 Total 100 
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Inference: Based on the above results, it has been inferred that around 50% of API of size 
75 were retained in #200 mesh. Similarly 42%, 6%, 2% of API having size of 106, 63 and 
150 were retained in #140, #230, and #100 meshes respectively. 
4.3.4. DRUG EXCIPIENT COMPATIBILITY STUDIES 
The compatibility of drug and formulation components is important prerequisite before 
formulation. It is therefore necessary to confirm that the drug does not react with the polymers 
and excipients under experimental conditions and affect the shelf life of product or any other 
unwanted effects on the formulation. 
As a part of the product development, the compatibility of various excipients with active was 
evaluated. 
According to the functional category these excipients were mixed in different ratios with drug.  
Excipients are mixed with the Escitalopram Oxalate (API) in following ratios. 
 
Vial in exposed condition for 1 month. Observations for physical appearance are made at 
initial, 2 week, and 4week, the samples were withdrawn for analysis of following parameter: 
 Description 
 Related substances 
 Results of the above excipients were used to fabricate robust formulation of Escitalopram 
Oxalate Tablets. 
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Rationale for selection of the below mentioned ratios of actives with the excipients: 
The percentages of excipients were taken based on their maximum usage limits (as mentioned 
in the literature) along with Escitalopram Oxalate. 
Sample preparation:  
The individual excipient(s) were weighed as per the formula and mixed well with the API.  
From the individual drug mixtures made, 2 g was placed in each vial.  
1. The vials were closed with the stoppers and labeled with all the details.  
2. 3 vials were kept at each of the below mentioned intervals under study.  
3. 2 gm of the active weighed into three vials (per interval) and placed this along with drug – 
excipient blends for study. 
Table15: Composition for ECS studies 
S No Composition Ratio 
1.  API (Escitalopram oxalate) - 
2.  API + Microcrystalline Cellulose pH 200 1:10 
3.  API + Microcrystalline Cellulose pH 112 1:10 
4.  API + Microcrystalline Cellulose pH 102 1:10 
5.  API + Lactose monohydrate 1:10 
6.  API + Lactose anhydrous 1:10 
7.  API + Maize starch B 1:5 
8.  API + Methocel E5 (HPMC) 2:1 
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9.  API + Povidone (Kollidon  30) 2:1 
10.  API + Sodium starch glycolate (Glycolys) 2:1 
11.  API + Croscarmellose sodium (Ac-di-sol SD 711) 2:1 
12.  API + Magnesium stearate (Synpro Magnesium stearate VG) 2:1 
13.  API + Colloidal silicon dioxide (Aerosil 200 pharma) 2:1 
14.  API + Talc ( Luzenac Pharma UM) 2:1 
15.  API+ Opadry white 4:1 
 
Sampling Schedule 
The prepared drug and excipient mixtures were evaluated at various intervals for Related 
Substances by HPLC as per the following conditions and time intervals 
S. No. Storage condition / Packing Sampling intervals 
1 Initial Initial 
2 40 ± 2 °C / 75 ± 5% RHGlass vial  
2 weeks 
4 weeks 
3 25°C/60% RH Glass Vial 2 weeks,4 weeks 
4 Room temperature Control sample 
 
4.3.5.SOLUBILITY STUDIES 
Escitalopram Oxalate is classified under class I according to BCS i.e; highly permeable and 
highly soluble. Solubility studies of Escitalopram oxalate were conducted at all pH ranges 
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from 1 to 12. The solubility of API was determined by dissolving the highest unit dose of the 
drug in 250 ml of buffer adjusted between pH 1.0 and 12.0 
Solubility Study: 
 Solubility study was performed at room temperature or ambient temperature. 
 250 ml of solvent or medium was taken into 250 ml volumetric flask in which the 
solubility of the Escitalopram Oxalate was to be established. 
 Escitalopram Oxalate equivalent to 18 mg was added 
 Ultrasonicated for 15 minutes with handshaking until the material was completely 
dissolved. 
 Solution was filtered through 0.45 µm filter to get clear solution. Filtered solution was 
diluted to get a concentration approximately equal to that of standard preparation. 
 Content of Escitalopram Oxalate was estimated by HPLC method. 
Amount of the Escitalopram Oxalate dissolved was calculated by using the following formula. 
The quantity of the Escitalopram Oxalate dissolved in percentage (wt/v): 
                A      Std.wt.      Test dil.       Std. purity       100 
             Q =    ----- x ----------- x -----------x --------------x---------------x100 
               B      Std. dil         test wt.        100          Test purity 
A= Response of the test solution. 
B= Response of the standard solution. 
The actual amount of Escitalopram Oxalate dissolved in mg 
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             Q x Wt 
     m = --------------- 
                 100 
4.4. FORMULATION DEVELOPMENT OF ESCITALOPRAM OXALATE 
TABLETS 20 mg 
Based on preformulation data and literature review, following strategies are used for 
formulation development i.e 
1. Direct compression method 
2. Dry granulation method 
3. Wet granulation method 
a. Aqueous granulation 
b. Non aqueous granulation 
After formulating the finished dosage forms by any of the above strategy, the finished dosage 
forms are charged for stability according to ICH guidelines. Finally the samples are analyzed 
by HPLC whether the release of drug from the formulation is within the specifications or not 
and for drug content. 
4.4.1.DIRECT COMPRESSION METHOD 
STEPS IN DIRECT COMPRESSION 
 STEP 1. WEIGHING:  
Weighed the required quantities of API other dry mix materials as per table given separately. 
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STEP2.  SIFTING: 
Sifted the API and other dry mix materials through #40 mesh and mixed the blend in a poly 
bag for uniform distribution of API. 
STEP3. LUBRICATION: 
Required amount of Magnesium stearate was weighed, passed through #80 mesh and blended 
with blend from step 2 for 5 min. 
STEP4. COMPRESSION: 
The granules obtained were compressed with 11.64 × 7.0 mm oval shaped standard concave 
punches using 17 station compression machine. 
S.no CONTENTS F1 (Mg/ tab) F2 (Mg/ tab)  F3 (Mg/ tab) 
1 Escitalopram Oxalate 25.55 25.55 25.55 
2 
Microcrystalline cellulose   
(Avicel PH102) 
209.45 207.45 - 
3 
Microcrystalline cellulose   
(Avicel PH112) 
- - 107.45 
4 
Microcrystalline cellulose   
(Avicel PH200) 
- - 100 
5 Sodium starch glycolate 10 10 10 
6 Colloidal silicondioxide 2.5 3.5 2.5 
7 Magnesium stearate 2.5 3.5 4.5 
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Formulations with Direct compression strategy: 
Table 16: Compilation of Escitalopram oxalate tablet by DC Strategy 
Lubricated blend parameters: 
S.No Parameters F1 F2 F3 
1 Bulk density(g/ml) 
Premix 
0.373 0.41 0.412 
2 Tapped density 0.552 0.508 0.477 
3 Cars index 32.42 19.5 13.62 
4 Hausners ratio 1.48 1.24 1.16 
 
Table 17: Parameters for DC strategy: 
Tablet parameters: 
S.No Parameters F1 F2 F3 
1 Weight(mg) 250 250 250 
2 Hardness(kp) 15.3-17.0 15.5-17.3 17.7-19.6 
3 Thickness(mm) 4.89-4.94 4.88-4.92 4.09-4.19 
4 Disintegration Time 4.55-5.32 4.59-5.21 4.57-5.24 
 
  
           Total tablet weight(mg) 250 250 250 
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4.4.2.DRY GRANULATION METHOD 
STEPS IN DRY GRANULATION 
 STEP 1. WEIGHING:         
Weighed the required quantities of all the dry mix materials as per table given separately. 
STEP2.  SIFTING: 
Sifted the drug and other dry mix materials through #40 mesh and mixed the blend in a poly 
bag for uniform distribution of API. 
STEP3.  COMPACTION:   
Sifted blend is compacted into ribbons/flakes using roll compactor. 
STEP5. SIZING & BLENDING OF GRANULES: 
The ribbons/flakes obtained were sized through #30 mesh. Required quantity extra granular 
material was weighed and passed through #40 mesh and blended along with granules for 15 
min. 
STEP6. LUBRICATION:Required amount of Magnesium stearate was weighed, passed 
through #80 mesh and blended with blend from step 5 for 5 min. 
STEP7. COMPRESSION: 
The granules obtained were compressed with 11.64 × 7.0 mm Oval shaped standard concave 
punches using 17 station compression machine. 
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Formulations with Drug in dry mix. 
Table 18: Compilation of Escitalopram oxalate Tablet by Dry Granulation 
S.no Contents F4 (mg/tab) F5(mg/tab) 
1 Escitalopram Oxalate 25.55 25.55 
2 
Microcrystalline cellulose 
(avicel PH102) 
204.45 - 
3 
Microcrystalline 
cellulose(avicelPH101) 
- 204.45 
 
4 
Hydroxy propyl methyl 
cellulose (methocel E5 PR 
LV) 
5 5 
Extra granular material 
5 Sodium starch glycolate 10 
6 Colloidal silicondioxide 2.5 
7 Magnesium stearate 2.5 
Average weight(mg) of core tablet 250 
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Table 19: Parameters for Dry Granulation Strategy 
 
 
 
 
 
Compressed tablet parameters:- 
Parameters F4 F5 
Weight(mg) 250 250 
Hardness(kp) 12-14 12-14 
Thickness(mm) 6.1-6.5 6.1-6.5 
Disintegration Time 5.01-5.49 5.08-5.37 
 
 
 
Parameters F4 F5 
Bulk density(g/ml) 
Premix 
0.338 0.341 
Tapped 
density(g/ml) 
0.466 0.439 
Carr’s index 27.46 22.32 
Hausners ratio 1.378 1.29 
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4.4.3.WET GRANULATION 
STEP 1. WEIGHING: 
Weighed the required quantities of API and other intra-granular materials as per table given 
separately. 
STEP2.  SIFTING: 
Sifted the API and other intra-granular materials through #40 mesh and mixed the blend in a 
poly bag for uniform distribution of API. 
STEP3.  GRANULATION:   
Sifted mixture is granulated using required amount of water for aqueous granulation and ipa 
for non-aqueous granulation. 
 STEP4. DRYING:Granules were dried at temperature at 60 °C until optimum LOD was 
obtained. 
STEP5. SIZING & BLENDING OF GRANULES: 
The granules obtained were sized through #30 mesh. Required quantity extra granular 
material was weighed and passed through #40 mesh along with granules. 
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STEP6. LUBRICATION: 
Required amount of Magnesium Stearate was weighed, passed through #80 mesh and blended 
with blend from step 5 for 5 min. 
STEP7. COMPRESSION: The granules obtained were compressed with 11.6 × 7.10 mm 
oval shaped standard concave punches using 17 station compression machine. 
Table 20: Compilation of Trials by Wet granulation process 
S.no Contents F6 F7  F8 F9 F10 F11 F12 
1 Escitalopram Oxalate (mg) 25.55 25.55 25.55 25.55 25.55 25.55 25.55 
2 
Microcrystalline cellulose 
(avicel PH101) (mg) 
206.2 204.2 203.2 200.2 200.2 200.2 200.2 
3 HPMC (mg) 3 5 5 5 5 5 5 
Binder addition 
4 Water q.s q.s q.s q.s - -   
5 IPA  - - - - q.s q.s q.s 
Extra granular materials 
6 Sodium starch glycolate (mg) 10 10 10 13 13 13 13 
7 Colloidal silicondioxide 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
8 Magnesium stearate (mg) 2.75 2.75 3.75 3.75 3.75 3.75 3.75 
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Average weight(mg) of core tablet 250 250 250 250 250 250 250 
Average weight(mg) of coated tablet 260 260 260 260 260 260 260 
 
Table 21: Parameters for Wet Granulation strategy 
Parameters F6 F7 F8 F9 F10 F11 F12 
Bulk 
density(g/ml) 
Premix 
0.338 0.341 0.39 0.465 0.39 0.342 0.343 
Hardness(kp) 9-10.5 
12.1-
13.7 
11.5-
13.2 
10.3-
11.2 
10.7-
11.8 
12.4-
13.3 
13.6-
14.1 
Thickness(mm) 
4.65-
4.80 
3.95-
3.99 
3.99-
4.02 
3.99-
4.01 
4.31-
4.33 
4.23-
4.27 
4.26-
4.28 
Disintegration 
Time 
4.10-
4.31 
4.44-  
4.49 
4.37-
5.09 
5.31-
5.54 
5.24-
5.37 
5.05-
5.28 
5.28-
5.43 
 
4.5.ANALYSIS OF REFERENCE/INNOVATOR PRODUCT 
With the help of analysis of the innovator product we will able to compare the results obtained 
of our formulated product and it was helpful for calculation of the (f1) dissimilarity & (f2) 
similarity dissolution factor. 
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Analysis of the innovator product was carried out for various physical parameters and In-vitro 
dissolution profile. 
For tablet (Parameters):- 
 Shape. 
 Thickness test. 
 Hardness test. 
 Friability test. 
 Weight Variation test. 
 In-vitro dissolution studies. 
4.6.EVALUATION OF TABLETS 
The compressed tablets were evaluated for different official and nonofficial tests .i.e.   
1) WEIGHT VARIATION TEST: 
Individual weights of 20 tablets were taken and the average weight was calculated by using 
the following formula. 
                                   (Weight of tablet-Average weight) 
Weight variation = ----------------------------------------------- ×100 
                                          Average weight of tablets 
 
Weight variation should not be more than 5%. 
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2) HARDNESS:- 
Hardness of the tablets was observed by the use of hardness tester. Desired hardness was 
13.0Kp 
3) THICKNESS:- 
Thickness of the tablets was calculated by the use of Digital Vernier calipers.  Desired 
thickness was 4.20 to 4.40mm. 
4)  DISSOLUTION:- 
The compressed tablets were evaluated for dissolution release profiles. It is carried out for 1 
hr study using USP-II (paddle type) apparatus. 
DISSOLUTION STUDY: 
Medium:  0.1N HCl 
                              Type of apparatus: USP-II (paddle type) 
RPM:  50 rpm 
Volume:  900ml 
Temperature: 37ºC± 0.5 
Time:  1 hr 
Time intervals:  5, 10,20,30,45 and 60 mins 
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Preparation of Dissolution media (0.1M HCl buffer): Add 16.6ml of HCl in a 2l 
volumetric flask and with some distilled water. Swirl to mix and add distilled water up to the 
mark of the volumetric flask. 
Test and Method of analysis 
Assay by HPLC 
Chromatographic conditions 
Instrument    : Shimadzu 1200 series, Injector, UV Detector and Recorder. 
Column        : ACE C18column, 100-mm × 4.6-mm column that contains 3-µm 
Wave Length: 239 nm. 
Flow rate     : 1.0 ml / min. 
Injection Volume: 10l. 
Column Temperature: 45ºC 
Run time: 10 min. 
Diluent:  0.1NHcl 
Retention time : About 6.4 minutes. 
Mobile Phase isPH5.2 buffer: methanol: ACN: 600:330:70  
 
 
 
Experimental Work 
 
 Page 69 
 
Buffer Preparation 
Dissolve accurately about 1.5 gms of anhydrous sodium acetate and 0.4ml of glacial acetic 
acid was added into one liter of water and ph 5.2 was adjusted to with 1N NaOH solution. 
Preparation of standard solution: (22.464 g/ml):Weigh and transfer accurately about 36 
mg of Escitalopram oxalate working standeard in 50 ml of volumetric flask and dissolve and 
dilute upto the mark with diluent. Pipette out 2 ml of the above solution in 250 ml volumetric 
flask and dilute upto mark with diluent. 
Preparation of test solution:Take a tablet dissolved in 900ml dissolution medium. 
Procedure of injection sequence: Injected 10 µl portion of the dissolution medium as blank, 
standard preparation, test preparation into the chromatogram, record the chromatogram and 
measure the response for the analyte peak. 
 
Calculations: 
Quantity of Escitalopram oxalate dissolved in nth time interval as 
 
   % of labeled amount =            AT *Ws *2* 900 * P 
 AS * 50* 50 *LC*100 
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Where, 
AT = average peak area of Escitalopram oxalate for test preparation, in the nth time 
interval 
AS = average peak area of Escitalopram oxalate for standard preparation 
Ws = weight of Escitalopram oxalate working standard taken in mg. 
P = potency of Escitalopram oxalate working standard calculated as API. 
LC = labeled amount of Escitalopram oxalate working standard calculated as API. 
n = time points 
5) ASSAY:- Assay is an indicative of the amount of the drug present in the dosage form. Here 
it gives the insight information about the substances of the process and about effect of 
changes. Decrease in assay % was insignificant and within limits for the formulations. 
Mobile Phase Preparation: ph5.2 buffer : methanol : ACN : 600:330:70 (v/v). 
Buffer Preparation: Dissolve accurately about 1.5 gms of anhydrous sodium acetate and 
0.4ml of glacial acetic acid was added into one liter of water and ph 5.2 was adjusted to with 
1N NaoH solution. 
Preparation of standard solution: (99.84 g/ml): 
Weigh and transfer accurately about 32 mg of Escitalopram oxalate working standeard in 50 
ml volumetric flask ,add 5ml of methanol and dissolve completely and sonicate for few 
seconds and make to the volume to  50ml with mobile phase and then further dilute 5 ml to 25 
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ml with water. Pipette out 2 ml of the above solution in 250 ml volumetric flask and dilute 
upto mark with diluent. 
Preparation of test solution: (100 g/ml): 
Weigh accurately 20 tablets of Escitalopram oxalate tablets crush and weigh the crushed 
powder equivalent to 100mg of Escitalopram into a 200ml volumetric flask, to this add 20 ml 
of buffer shake vigoursly for 10 mins add 100ml of methanol to this flask shake for one 
additional min and sonicate for 10 mins and make up the volume with mobile phase with up to 
the mark filter through 0.45micrometer filter further dilute 5ml to 25ml with water. 
Procedure of injection sequence: 
Injected 10 µl portion of the dissolution medium as blank, standard preparation, test 
preparation into the chromatogram, record the chromatogram and measure the response for 
the analyte peak. 
Chromatographic conditions 
Instrument  : Shimadzu 1200 series, Injector, UV Detector and Recorder. 
Column  : ACE C18column, 100-mm × 4.6-mm column that contains 3-µm 
Wave Length   : 239 nm. 
Flow rate  : About 1.0 mL / min. 
Injection Volume : 10l. 
Column Temperature: 45ºC 
Run time   : 10 min. 
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Diluent   : pH 5.2 buffer : methanol : ACN(600:330:70) 
Retention time  : About 6.4 minutes. 
Procedure: Inject 10 µl portion of the diluents as blank, standard preparation, test preparation 
into the chromatogram, record the chromatogram and measure the response for the analyte 
peak. 
Calculations:- 
Assay    : Assay(mg/tab) : AT* WR*5*200*25*PR*Avg Wt*324.4*100 
                                      AR*50*25*WS*5*LA*100*414.4 
Where,AT = avearge peak area of Escitalopram oxalate for test preparation. 
AR = average peak area of Escitalopram oxalate for standard preparation. 
WR = weight of Escitalopram oxalate in slandered solution in mg 
Ws = weight of Escitalopram oxalate sample taken in sample preparation mg. 
PR = purity of Escitalopram oxalate working standard calculated as API. 
LA = labeled amount of Escitalopram oxalate per tablet 
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5.1. PREFORMULATION STUDIES 
 
5.1.1. Evaluation of tablet 
 
Table 22: Results of physical evaluation of tablet 
Physical  
parameter 
F1 F2 F3 F4 F5 F6 
Weight variation (%) 8 5.5 5 4.7 4.1 1.5 
Hardness 
(Kp) 
15.3-17.0 15.5-17.3 17.7-19.6 12.4-14.1 12.9-14.5 22.5-24.7 
Thickness 
(mm) 
4.89-4.94 4.88-4.92 4.09-4.19 6.1- 6.5 6.1- 6.5 3.98-4.04 
Disintegration Time 4.55-5.32 4.59-5.21 4.57-5.24 5.01-5.49 5.08-5.37 4.10-4.31 
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Table no.23. Results of physical evaluation of tablet 
 
Physical  parameter F7 F8 F9 F10 F11 
F12 
 
Weight variation (%) 0.9 0.2 0.17 0.44 0.21 
0.17 
 
Hardness 
(Kp) 
18.9-19.7 11.7-12.9 14.3-15.3 10.7-11.8 12.4-13.3 
13.6-14.1 
 
Thickness 
(mm) 
 
4.01-4.07 4.14-4.19 4.05-4.10 4.31-4.33 4.23-4.27 4.26-4.28 
Disintegration Time 
 
4.24-4.49 4.37-5.09 5.31-5.54 5.24-5.37 5.05-5.28 5.28-5.43 
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5.1.2. Drug-Excipient Compatibility Studies 
Table no.24 
S. 
No 
Composition Ratio 
Initial 
Observation 
Final 
observation 
(40°C/75% 
RH) 
Final 
observation 
(25°C/60% 
RH) 
Conclusion 
2nd 
week 
4th 
week 
2nd 
week 
4th 
week 
1 
API 
(Escitalopram 
oxalate) 
- White White White White White Compatible 
2 
API + 
Microcrystalline 
Cellulose pH 
200 
1:10 White White White White White Compatible 
3 
API + 
Microcrystalline 
Cellulose pH 
112 
1:10 White White White White White Compatible 
4 
API + 
Microcrystalline 
Cellulose pH 
102 
1:10 White White White White White Compatible 
5 
API + Lactose 
monohydrate 
1:10 White White White White White Compatible 
6 
API + Lactose 
anhydrous 
1:10 White White White White White Compatible 
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7 
API + Maize 
starch B 
1:05 White White White White White Compatible 
8 
API + Methocel 
E5 (HPMC) 
2:01 White White White White White Compatible 
9 
API + Povidone 
(Kollidon  30) 
2:01 White White White White White Compatible 
10 
API + Sodium 
starch glycolate 
(Glycolys) 
2:01 White White White White White Compatible 
11 
API + 
Croscarmellose 
sodium (Ac-di-
sol SD 711) 
2:01 White White White White White Compatible 
12 
API + 
Magnesium 
stearate (Synpro 
Magnesium 
stearate VG) 
2:01 White White White White White Compatible 
13 
API + Colloidal 
silicon dioxide 
(Aerosil 200) 
2:01 White White White White White Compatible 
14 
API + Talc ( 
Luzenac 
Pharma UM) 
2:01 White White White White White Compatible 
15 
API+ Opadry 
white 
4:01 White White White White White Compatible 
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5.1.3. Estimation of λmax   
 
 
Fig no.1 Estimation of λmax 
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5.2. Standard calibration values: 
Table no.25 
Conc( µg/ml) Absorbance(nm) 
0 0 
2 0.0813 
4 0.1586 
6 0.2349 
8 0.3087 
10 0.3824 
 
 
                    Fig no.2       Standard Calibration Profile of Escitalopram oxalate 
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5.3. DISSOLUTION STUDIES 
Dissolution profile for Escitalopram oxalate tablets:   
Table 26: Reference tablet dissolution study data 
 
S.no 
Time 
(min) 
  % Drug Dissolved 
Sample-
1 
Sample-
2 
Sample-
3 
Sample-
4 
Sample-
5 
Sample-
6 
MEAN(Q) 
1 0 0 0 0 0 0 0 0 
2 5 73 78 76 79 74 75 76.3 
3 10 81 83 82 82 83 86 82.8 
4 15 91 92 92 91 91 91 91.3 
5 20 96 98 97 98 97 98 97.3 
6 30 101 102 101 101 101 104 101.6 
7 45 102 102 101 101 101 102 101.5 
8 60 101 102 101 101 101 101 101.1 
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Dissolution data of innovated drug product: 
 
 
 
Fig no.2. Dissolution profile of innovated drug product 
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Comparative dissolution profiles: 
 
Table no.27: Dissolution profile of F1: 
 
 
 
                                          Fig no.3. Dissolution profile of F1 
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S.no 
               
Time 
(min) 
%Drug Dissolved 
Sample-
1 
Sample-
2 
Sample-
3 
Sample-
4 
Sample-
5 
Sample-
6 
MEAN(Q) 
1 0 0 0 0 0 0 0 0 
2 5 73 89 64 72 91 60 74.83 
3 10 101 91 98 94 81 68 74 
4 15 101 96 108 112 91 86 99 
5 20 102 109 112 114 99 90 104.3 
6 30 102 112 114 101 106 101 106 
7 45 101 106 102 104 111 101 104.1 
8 60 99 101 101 102 104 100 101.1 
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Table no.28. Dissolution profile of F2 
 
 
 
 
Fig no.4. Dissolution profile of F2 
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S.no 
Time 
(min) 
  % Drug Dissolved 
Sample-
1 
Sample-
2 
Sample-
3 
Sample-
4 
Sample-
5 
Sample-
6 
MEAN(Q) 
1  0  0  0  0  0  0  0  0  
2  5  76  64  72  71  61  59  67.1  
3  10  79  71  74  76  79  81  76.6  
4  15  81  66  78  81  84  85  79.1  
5  20  89  96  92  101  93  98  94.8  
6  30  106  89  101  111  102  102  101.8  
7  45  101  92  98  112  101  99  100.5  
8 60 102 98 99 104 98 100 100.1 
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Table no.29. Dissolution profile of F3 
 
 
 
 
Fig no.5. Dissolution profile of F3 
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Innovator
F3
S.no 
Time 
(min) 
    % Drug Dissolved 
Sample-
1 
Sample-
2 
Sample-
3 
Sample-
4 
Sample-
5 
Sample-
6 
MEAN(Q) 
1  0  0  0  0  0  0  0  0  
2  5  82  79  76  81  74  79  78.5  
3  10  91  89  93  92  91  89  90.8  
4  15  96  92  93  93  92  90  92.6  
5  20  108  109  107  109  110  109  108.6  
6 30  111  109  108  109  111  109  109.5  
7 45  111  109  108  109  111  110  109.6  
8 60 106 104 102 102 104 101 103.1 
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Table no.30. Dissolution profile of F4 
 
 
 
fig no.6. Dissolution profile of F4 
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Sn.n0 Time(min) %drug release 
Sample-
1 
Sample-
2 
Sample-
3 
Sample-
4 
Sample-
5 
Sample-
6 
Mean-
(Q) 
1 0 0 0 0 0 0 0 0 
2 5 54 59 61 55 51 49 54.8 
3 10 69 71 66 63 59 58 64.3 
4 15 71 75 72 64 66 60 69.1 
5 20 74 78 77 69 71 74 73.8 
6 30 78 80 81 75 75 76 77.5 
7 45 81 85 86 81 86 82 83.5 
8 60 81 86 87 81 86 84 84.1 
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Table no.31:Dissolution profile of F5 
 
 
 
Fig no.7. Dissolution profile of F5 
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S.No Time(min) 
% drug release 
Sample-
1 
Sample-
2 
Sample-
3 
Sample-
4 
Sample-
5 
Sample-
6 
Mean-
(Q) 
1 0 0 0 0 0 0 0 0 
2 5 69 74 66 67 66 69 68.5 
3 10 71 77 79 71 76 78 75.3 
4 15 74 78 79 75 77 80 77.1 
5 20 78 79 81 79 80 82 79.8 
6 30 80 82 84 86 86 87 84.1 
7 45 82 85 86 87 88 89 86.1 
8 60 86 89 90 91 92 94 90.3 
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Table no.32. Dissolution profile of F8 
 
 
 
Fig no.8 Dissolution rofile of F8 
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S.no 
Time 
(min) 
       % Drug Dissolved 
Sample-
1 
Sample-
2 
Sample-
3 
Sample-
4 
Sample-
5 
Sample-
6 
MEAN(Q) 
1 0 0 0 0 0 0 0 0 
2 5 59 66 68 71 66 67 66.1 
3 10 71 69 76 72 69 76 72.1 
4 15 82 81 80 86 89 79 82.8 
5 20 88 92 86 88 91 84 88.1 
6 30 91 90 92 89 88 88 89.6 
7 45 92 91 92 90 88 96 91.5 
8 60 92 91 93 90 88 91 90.8 
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Table no.33. Dissolution profile of F9 
 
 
  
Fig no.9 Dissolution profile of F9 
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S.No 
 
Time in 
Mins 
     %Drug Dissolved 
Sample-
1 
Sample-
2 
Sample-
3 
Sample-
4 
Sample-
5 
Sample-
6 
MEAN(Q) 
1 0 0 0 0 0 0 0 0 
2 5 82  83  81  88  89  87  85  
3 10 86  87  88  89  91  88  88.1  
4 15 99  98  98  96  98  99  98  
5 20 104  103  106  102  99  98  102  
6 30 104  104  102  101  100  99  101.6  
7 45 101  102  102  101  101  100  101.1  
8 60 101  102  103  102  101  99  101.3  
Investigational Reports 
 
 Page 88 
 
Table no.34 Dissolution Profile of F9 (400C/75% RH – 1 month) 
 
 
 
 
                                      Fig no.10. Dissolution Profile of F9 (1 month) 
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S.No 
 
Time in 
Mins 
     % Drug Dissolved 
Sample-
1 
Sample-
2 
Sample-
3 
Sample-
4 
Sample-
5 
Sample-
6 
MEAN(Q) 
1 0 0 0 0 0 0 0 0 
2 5 40 43 38 40 39 42 28 
3 10 49 53 52 47 49 49 33 
4 15 53 57 59 65 56 63 58.8 
5 20 68 67 70 72 71 70 47 
6 30 81 78 79 76 78 75 61 
7 45 84 83 87 85 84 86 72 
8 60 98 101 94 94 95 97 78 
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Table no.35Dissolution profile of F10 
S.No 
Time 
(min) 
   % Drug Dissolved 
Sample
1 
Sample
2 
Sample
3 
Sample
4 
Sample
5 
Sample
6 
MEAN 
(Q) 
1 0 0 0 0 0 0 0 0 
2 5 69  61  68  66  71  67  67  
3 10 81  89  82  84  79  82  82.8  
4 15 84 90 87 89 85 93 88 
5 20 95  92  96  99  99  101  97  
6 30 99  98  99  97  101  102  99.3  
7 45 101  103  100  101  106  108  103.1  
8 60 101  103  101  101  101  102  101.5  
 
 
 
Fig no.11 Dissolution profile of F10 
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Table no.36. Dissolution profile of F11 
S.No 
Time 
(min) 
                                     % Drug Dissolved 
Sample
1 
Sample
2 
Sample
3 
Sample
4 
Sample
5 
Sample
6 
MEAN 
(Q) 
1 0 0 0 0 0 0 0 0 
2 5 80  69  69  70  76  78  73.6  
3 10 82  85  89  83  91  93  87.1  
4 15 86 91 92 95 99 96 93.1 
5 20 91  96  98  99  101  101  97.6  
6 30 100  102  101  101  101  101  101  
7 45 103  103  104  102  101  99  102  
8 60 102  101  101  100  100  101  100.8  
 
 
 
Fig no.12. Dissolution profile of F11 
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Table no37 Dissolution profile of F12 
S.No 
Time 
(min) 
      % Drug Dissolved 
Sample
1 
Sample
2 
Sample
3 
Sample
4 
Sample
5 
Sample
6 
MEAN 
(Q) 
1 0 0 0 0 0 0 0 0 
2 5 80  84  86  81  88  84  83.8  
3 10 91  92  91  90  94  92  91.6  
4 15 95 94 96 92 95 96 94.6 
5 20 96  98  98  97  96  98  96.6  
6 30 102  99  99  101  101  99  100.1  
7 45 101  102  102  101  99  102  101.1  
8 60 101  101  103  102  101  102  101.6  
 
 
Fig no.13. Dissolution profile of F12 
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CHROMATOGRAMS FOR CONFIRMATORY BATCH 
DISSO BLANK 
 
DISSO STANDARD 
 
DISSO SAMPLE 
 
0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 min
0
25
50
75
100
125
150
mV
Detector A:239nm 
0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 min
0
10
20
30
40
50
60
70
80
mV
Detector A:239nm 
ES
CI
TA
LO
PR
AM
/6
.5
52
/6
70
55
0
0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 min
0
10
20
30
40
50
60
70
80
mV
Detector A:239nm 
ES
CI
TA
LO
PR
AM
/6
.5
56
/6
71
93
4
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STABILITY STUDIES  
Table 38: Related Substances (25/60) after 15 days 
S.No 
Name of Drug/ 
Excipient 
Ratio 
Related Substances   
Imp-A Imp-B Imp-C Total 
1 
API + 
Microcrystalline 
Cellulose pH 112 
1:10 0.004 0.09 0.003 0.04 
2 
API + 
Microcrystalline 
Cellulose pH 102 
1:10 0.004 0.08 0.006 0.03 
3 
API + Lactose 
monohydrate 
1:10 0.004 0.06 0.061 0.033 
4 
API + Lactose 
anhydrous 
1:10 0.043 0.07 0.004 0.037 
5 API + Maize starch B 1:05 0.07 0.09 0.067 0.005 
6 
API + Sodium starch 
glycolate (Glycolys) 
2:01 0.025 0.049 0.0053 0.05 
7 
API + Magnesium 
stearate (Synpro 
Magnesium stearate 
VG) 
2:01 0.004 0.08 0.006 0.03 
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Table 39: Related Substances (25/60) after 30 days 
S.No 
Name of Drug/ 
Excipient 
Ratio 
Related Substances   
Imp-A Imp-B Imp-C Total 
1 
API (Escitalopram 
oxalate) 
- 0.07 0.07 0.09 0.24 
2 
API + Microcrystalline 
Cellulose pH 112 
1:10 0.004 0.09 0.003 0.04 
3 
API + Microcrystalline 
Cellulose pH 102 
1:10 0.004 0.08 0.006 0.03 
4 
API + Lactose 
monohydrate 
1:10 0.004 0.06 0.061 0.033 
5 
API + Lactose 
anhydrous 
1:10 0.043 0.07 0.004 0.037 
6 API + Maize starch B 1:05 0.07 0.09 0.067 0.005 
7 
API + Sodium starch 
glycolate (Glycolys) 
2:01 0.025 0.049 0.0053 0.05 
8 
API + Magnesium 
stearate (Synpro 
Magnesium stearate 
VG) 
2:01 0.004 0.08 0.006 0.03 
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Table 40: Related Substances (40/75) after 15 days 
S.No 
Name Of Drug/ 
Excipient 
Ratio 
Related Substances   
Imp-A Imp-B Imp-C Total 
1 
API (Escitalopram 
oxalate) 
- 0.15 0.15 0.07 0.37 
2 
API + 
Microcrystalline 
Cellulose pH 200 
1:10 0.025 0.05 0.0053 0.061 
3 
API + 
Microcrystalline 
Cellulose pH 112 
1:10 0.005 0.09 0.003 0.041 
4 
API + 
Microcrystalline 
Cellulose pH 102 
1:10 0.004 0.026 0.006 0.036 
5 
API + Lactose 
monohydrate 
1:10 0.004 0.06 0.061 0.125 
6 
API + Lactose 
anhydrous 
1:10 0.023 0.07 0.004 0.033 
7 API + Maize starch B 1:05 0.07 0.09 0.067 0.022 
8 
API + Sodium starch 
glycolate (Glycolys) 
2:01 0.025 0.049 0.0053 0.042 
9 
API + Croscarmellose 
sodium (Ac-di-sol SD 
711) 
2:01 0.004 0.09 0.003 0.047 
10 
API + Magnesium 
stearate (Synpro 
Magnesium stearate 
VG) 
2:01 0.004 0.08 0.006 0.09 
11 
API + Talc ( Luzenac 
Pharma UM) 
2:01 0.033 0.07 0.002 0.037 
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Table 41: Related Substances (40/75) after 30 days 
S.No 
Name Of Drug/ 
Excipient 
Ratio 
Related Substances   
Imp-A Imp-B Imp-C Total 
1 
API (Escitalopram 
oxalate) 
- 0.15 0.15 0.1 0.4 
2 
API + Microcrystalline 
Cellulose pH 200 
1:10 0.025 0.049 0.0053 0.21 
3 
API + Microcrystalline 
Cellulose pH 112 
1:10 0.004 0.09 0.03 0.04 
4 
API + Microcrystalline 
Cellulose pH 102 
1:10 0.004 0.08 0.006 0.09 
5 
API + Lactose 
monohydrate 
1:10 0.04 0.06 0.061 0.033 
6 
API + Lactose 
anhydrous 
1:10 0.043 0.07 0.004 0.054 
7 API + Maize starch B 1:05 0.07 0.09 0.067 0.19 
8 
API + Povidone 
(Kollidon  30) 
2:01 0.08  0.09  0.05   0.22 
9 
API + Sodium starch 
glycolate (Glycolys) 
2:01 0.025 0.049 0.0047 0.08 
10 
API + Croscarmellose 
sodium (Ac-di-sol SD 
711) 
2:01 0.004 0.09 0.009 0.11 
11 
API + Magnesium 
stearate (Synpro 
Magnesium stearate 
VG) 
2:01 0.004 0.08 0.009 0.092 
12 
API + Colloidal silicon 
dioxide (Aerosil 200) 
2:01 0.004 0.06 0.056 0.12 
     13 
API + Talc ( Luzenac 
Pharma UM) 
2:01 0.041 0.06 0.004 0.105 
     14 API+ Opadry white 4:01 0.07 0.1 0.067 0.12 
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6.Results & Discussions 
The present study was undertaken to formulate Escitalopram oxalate immediate release tablets. 
The study involves pre-formulation studies of drug and excipients, formulation and processing 
development along with evaluation of tablets made with the optimized formulation. Finally 
tablets were evaluated by in vitro methods.  
6.1.PREFORMULATION STUDIES 
Drug Excipients Compatibility Study 
Physical observation 
Compatibility with excipients was confirmed by HPLC studies. The pure drug and along with its 
formulation excipients were subjected to compatibility studies & studies were carried out by 
mixing definite proportions of drug and excipients and kept in glass vials which are stored at 
40°C ±2°C&75± 5%RH and 25°C ±2°C + 60% RH for one month .Physical observation of 
sample was done every week for any colour change or lump formation, the results of the physical 
observation and Related Substances were shown in Table no.24 
6.2.DISSOLUTION STUDIES 
F1: In the first trial F1, 25.55mg/tab of API (equivalent to 20mg of Escitalopram), 209.45mg/tab 
of microcrystalline cellulose (Avicel PH 102), were sifted through #40 and then blended and 
lubricated with extra granular material and finally compressed to tablets.which is shown in table 
no.27 
Conclusion: Physical parameters of tablets were found to be unsatisfactory. Very poor flow of 
blend was observed. Picking of tablets observed at the time of compression.   
F2:  Same composition as of F1 but diluent decreased by 2mg and colloidal silicon dioxide and 
magnesium stearate was increased by 1 mg, then blended and lubricated, finally compressed to 
tablets.shown in table no.28 
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Conclusion: Flow of blend was improved. Poor content uniformity of tablets observed. 
Dissolution studies were found to be on lower side. Only 82% of drug dissolved in 1hr. 
Dissolution rate was also low when compared to Reference. (100% at 1 hr). 
F3:  In these formula diluents were changed from Avicel PH102 to mixture of Avicel PH200 and 
Avicel PH 112 (100mg + 107.45mg). The above materials were sifted through #40, blended and 
lubricated with extra granular material and finally compressed to tablets.shown in table no.29 
Conclusion: Flow of blend was good. Tablet assay is found to be on higher side i.e.,108% 
(standard limit 95 to 105%). Poor content uniformity of tablets observed. 
F4 
Objective: To take a trial by Dry granulation process. 
Conclusion: compacts are formed with very low hardness, poor flow of final blend was 
observed. Dullness of tablet observed.shown in table no.30 
F5 
Objective: To take a trial by change of diluent. 
 
Conclusion: Flow was improved when compared to F4 but still rat holing was observed when 
observed through funnel. Compacts are formed with low hardness, no change in strength of 
compacts observed even with increasing pressure between rollers.shown in table no.31 
F6: In the first trial F6, API and other intragranular materials were sifted through #40. The above 
materials were granulated using water as granulating agent. Final dried granules were sifted 
through #30, blended and lubricated with extra granular material and finally compressed to 
tablets.shown in table no.32 
Conclusion: fines percentage is very high in the dried blend. Physical parameters of tablets were 
found unsatisfactory.  
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F7:  Same composition as that of F6 but amount of HPMC was increased 2mg more in intra-
granular portion. The above materials were granulated using water as granulating agent. Final 
dried granules were sifted through #30, blended and lubricated with extra granular material and 
finally compressed to tablets.shown in table no.33 
Conclusion: Physical parameters of tablets were found satisfactory. But sticking problem is 
appearing 
F8:  Same composition as that of F7 but stearate was increased by 1 mg in extra-granular 
portion. The above materials were granulated using water as binding agent. Final dried granules 
were sifted through #30, blended and lubricated with extra granular material and finally 
compressed to tablets.shown in table no.34 
Conclusion: Physical parameters of tablets were found satisfactory. Dissolution studies were 
found to be on lower side. 90% of drug dissolved at 1hr of dissolution study. Dissolution rate 
was improved when compared to f2 but less when compared to Reference where 100% of drug 
was dissolved at 1hr. 
F9:  In this batch disintegrant quantity was increased by 3mg in extra-granular portion which is 
compensated with the diluent. The above materials were granulated using water as granulating 
agent. Final dried granules were sifted through #30, blended and lubricated with extra granular 
material and finally compressed to tablets.shown in table no.35 
Conclusion: Granulation and Compression parameters were found to be satisfactory. Dissolution 
data was found to be similar when compared to Reference. Complete release of drug was 
observed in a similar way to that of Reference product. Then tablets were packed in PVC blister 
and stored at ICH conditions (25˚C/60%RH, 30˚C/65%RH and 40˚C/75%RH). Dissolution drop 
was observed after 1 month of stability charging and even the hardness of the tablet was 
increased. 
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F10:  Same Formula as that ofF9but the above materials were granulated using IPA as 
granulating agent instead of water and temperature was reduced to 45˚C during drying.  Final 
dried granules were sifted through #30, blended and lubricated with extra granular material and 
finally compressed to tablets and coated with aqueous dispersed coating solution.shown in table 
no.36 
Conclusion: Granulation parameters were found satisfactory. Compression parameters were 
found to be satisfactory. Dissolution studies were found to be good. But in final tablets IPA 
content crosses the official limit. (3000 ppm) 
F11: In this trial, same formula as of F10 and compression was done and tablets are coated with 
non-aqueous coating solution (IPA: DCM with 40:60).shown in table no.36 
Conclusion: Here also IPA content is more than the permitted limit. 
F12: In the formula same as F11 but granules drying temperature was increased to 55˚C and 
remaining process was same as above.(Final dried granules were sifted through #30, blended and 
lubricated with extra granular material and finally compressed to tablets and coating done with 
mixture of IPA and DCM in the ratio40:60.) shown in table no.37 
Conclusion: Granulation parameters were found satisfactory. Compression parameters were 
found to be satisfactory. Dissolution studies were found to be good and final tablets IPA content 
is also complying official limits. 
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6.3.Stability studies: 
Impurity was less than 0.5% According to guidelines on impurity of drug product the drug 
product containing 20 mg dose /day acceptance criteria is 0.5%.shown in table no.38,39,40,41. 
Conclusions: By observing the data obtained from compatibility study, which includes physical 
appearance and related substances done for the samples it can be concluded that: 
 No change in physical description was observed. 
 No significant increase in impurities was observed. 
Hence it can be concluded that the excipients used in the formulation are considered compatible 
with the active ingredient and it will be further concluded in the final formulation stability 
studies. 
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7. SUMMARY AND CONCLUSION 
The aim of this study was to develop stable Escitalopram oxalate Immediate Release 
tablets which have more chances for drop in dissolution during stabiltiy and comparing with 
marketed product. Escitalopramoxalate  comes under the category of Antidepressant and 
anxiolytic. In this study Escitalopram oxalate tablets were prepared by using a range of 
excipients including diluents and functional excipients and formulated by direct compression, 
dry granulation and wet granulation of which direct compression and dry granulation process 
were failed due to poor content uniformity of dosage form and wet granulation was successful in 
which non aqueous granulation with non aqueous coating was found to be good which showed 
very less impurity generation during stability studies. Different invitro studies were performed 
and were compared with that of reference and the one with wet granulation were found to be 
satisfactory. 
The conclusion of the study is as follows: 
 The tablets prepared were found to be within the official limits with respect to hardness, weight 
variation, drug content, thickness etc 
 Among all the formulations done, the formulation with non aqueous granulation was found to be 
good which showed very less drop in the dissolution profile during stability where in the drop of 
dissolution was high in aqueous granulation during its stability study. 
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CONCLUSION 
It can be concluded that wet granulation process with non aqueous granulation(with IPA) 
and with non aqueous coating was found to be optimum for the manufacturing of Escitalopram 
oxalate tablets as the stability results were found to be good with no impurity issues and stable 
dissolution data. The tablets prepared are comparable with that of the reference in all aspects and 
is a stable formulation. 
Formulation-F12 containing Escitalopram oxalate 25.55 mg per tablet and developed 
using non aqueous granulation with non aqueous coating is similar and equal to the innovator 
product in respect of all tablets properties and dissolution profile. 
Hence the study resulted in the development of Escitalopram oxalate tablets comparable 
to the innovator product for Escitalopram oxalate which is stable. 
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